Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma

Abstract. The serum soluble CD163 (sCD163) is elevated in patients with inflammatory disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. In this study, serum level of sCD163 was measured by using...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Qinglin Fei, MD, Yu Pan, MD, PhD, Xingxing Yu, MD, Ronggui Lin, MD, PhD, Xianchao Lin, MD, PhD, Heguagn Huang, MD
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Wolters Kluwer Health/LWW 2020-09-01
Loạt:Journal of Pancreatology
Truy cập trực tuyến:http://journals.lww.com/10.1097/JP9.0000000000000055

Những quyển sách tương tự